



## Nominations for new members of UCB's Board of Directors

**Brussels (Belgium), 25 March 2016 – 7:00 AM (CET)** – Today, UCB SA is publishing its convening notice and agenda for its Annual General Meeting which will take place on April 28, 2016. In the agenda, the Board of Directors of UCB SA is proposing to appoint MM. Pierre Gurdjian and Ulf Wiinberg as new independent Directors at the company's next General Assembly.

Pierre Gurdjian is currently Chairman of the Board of Directors of the Université Libre de Bruxelles and he teaches a graduate course in CEO Leadership at the Solvay Business School. He is also very active in the field of Philanthropy and Education. Previously he worked for nearly three decades at the management consultancy firm McKinsey & Company as a Senior Partner and, from 2005 to 2012, as head of the Belgian office.

Ulf Wiinberg is a seasoned healthcare industry professional. At Wyeth, he was President of the global consumer health care business, and later President for the European pharma business. Ulf was also CEO of Lundbeck for several years, a Nordic pharmaceutical company specialized in brain diseases. Ulf has served on the boards of several healthcare industry associations. He is today a non-executive Board member at Alfa Laval, a Swedish industrial company, and Nestle Health and Science; he is also Chairman of Avillion.

Also, at the next General Assembly on April 28, 2016, the mandates of Harriet Edelman and Charles-Antoine Janssen will be proposed for renewal and the mandate of Tom McKillop will come to an end. "After two successful terms as Board member, Tom McKillop, will be stepping down. UCB's Board of Directors and Executive Committee wish to express their sincere thanks to Tom for his guidance during the transformation phase the company went through in the last decade and for helping UCB build a position of strength with solid and sustainable growth prospects" said Gerhard Mayr, Chairman of the Board of Directors and Jean-Christophe Tellier, CEO of UCB.

The two new independent Board member candidates have been selected based on their large management and industry experience with a view to further broadening the Board's competence portfolio. Pending the approval by the next General Assembly, the new Board will include a majority of Independent Board members namely the following directors: Alice Dautry, Kay Davies, Albrecht De Graeve, Harriet Edelman, Norman J. Ornstein, Pierre Gurdjian and Ulf Wijnberg. Other members of the UCB Board of Directors are: Gerhard Mayr, Chairman, Evelyn du Monceau, Vice Chair, Jean-Christophe Tellier,

Executive Director, Charles-Antoine Janssen, Cyril Janssen and Cédric van Rijckevorsel.

Biographies of Pierre Gurdjan and Ulf Wiinberg can be found [here](#).

## For further information

### Corporate Communications

France Nivelles,  
Global Communications, UCB  
T +32.2.559.91.78, [france.nivelles@ucb.com](mailto:france.nivelles@ucb.com)

Laurent Schots,  
Media Relations, UCB  
T +32.2.559.92.64, [laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

### Investor Relations

Antje Witte,  
Investor Relations, UCB  
T +32.2.559.94.14, [antje.witte@ucb.com](mailto:antje.witte@ucb.com)

Isabelle Ghellynck,  
Investor Relations, UCB  
T+32.2.559.9588, [isabelle.ghellynck@ucb.com](mailto:isabelle.ghellynck@ucb.com)

### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7500 people in approximately 40 countries, the company generated revenue of €3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

### Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.